GlassScriptPhysician profile
Atul Agrawal
NPI 1528146016
$8,070.58
in general payments reported to CMS, 2019-2025
34 companies · $2,907 in 2025
The $2,907 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $2,604 · 2024: $2,447 · 2025: $2,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,921 · Education: $37.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,920.66 |
| Education | $37.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,768.36 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Ucb, INC. | $987.51 | 2023-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $946.37 | 2023-2025 | Rinvoq |
| Pfizer INC. | $438.84 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $408.18 | 2023-2025 | Lupkynis |
| Janssen Biotech, INC. | $359.31 | 2022-2025 | Simponi Aria, Tremfya, Remicade |
| Astrazeneca Pharmaceuticals LP | $351.08 | 2023-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $333.09 | 2023-2025 | |
| Organon LLC | $262.61 | 2023-2025 | Hadlima, Renflexis |
| Mallinckrodt Hospital Products INC. | $255.27 | 2023-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $225.12 | 2024-2025 | Strensiq |
| Glaxosmithkline, LLC. | $218.18 | 2023-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $198.14 | 2025 | Adalimumab-Aacf, Idacio |
| Ani Pharmaceuticals, INC. | $138.13 | 2023-2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $133.52 | 2023 | Belsomra, Verquvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $133.22 | 2023-2025 | Octagam Immune Globulin (Human), Cutaquig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.35 | 2023-2025 | Ofev |
| Genentech USA, INC. | $109.97 | 2025 | Actemra |
| Lilly USA, LLC | $73.32 | 2023-2024 | Taltz |
| Sandoz INC. | $72.72 | 2023-2025 | Hyrimoz, Jubbonti |
| Celltrion USA INC. | $72.59 | 2023-2025 | Vegzelma, Yuflyma |
| E.R. Squibb & Sons, L.L.C. | $69.39 | 2024-2025 | Orencia |
| Horizon Therapeutics Plc | $61.19 | 2023 | Krystexxa |
| Kiniksa Pharmaceuticals International, Plc | $54.65 | 2024 | Arcalyst |
| Sobi, INC | $51.14 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $50.13 | 2023 | Arcalyst |
| Genzyme Corporation | $40.48 | 2023 | |
| Sanofi-Aventis U.S. LLC | $26.17 | 2023 | |
| Alnylam Pharmaceuticals INC. | $23.43 | 2024 | Givlaari |
| Ultragenyx Pharmaceutical INC. | $22.22 | 2023 | |
| Tonix Medicines, INC. | $20.60 | 2025 | Tonmya |
| Kyowa Kirin, INC. | $20.25 | 2023 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $17.63 | 2024 | Simlandi |
| Tersera Therapeutics LLC | $16.42 | 2025 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.